(Q35034764)

English

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

multicenter clinical trial

0 references

0 references

Gian Luca De Salvo

10

object named as

G L De Salvo

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

V Chiarion-Sileni

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M Guida

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

L Ridolfi

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A Romanini

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

P Del Bianco

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

J Pigozzo

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

S Brugnara

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

G Colucci

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

R Ridolfi

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Italian Melanoma Intergroup (IMI)

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

24 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1816-1821

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Treatment of metastatic melanoma: an overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111207

8 July 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Cisplatin increases sensitivity of human leukemic blasts to triazene compounds.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.178

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21610711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2011.178

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Dimensions Publication ID

0 references

Internet Archive ID

pubmed-PMC3111207

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35034764&oldid=2197175437"